Efficacy of Fremanezumab in Male Patients with Migraine and Documented Inadequate Response to 2-4 Classes of Migraine Preventive Treatments: Results of the Randomized, Placebo-controlled FOCUS Study

Antoinette Maassen Van Den Brink, PhD

AHSAM 2020 - Poster session
Published on August 27, 2020

2 minute listen

1 minute read

Key messages

  • This analysis evaluated the efficacy of fremanezumab in male migraine patients over 12 weeks of double-blind treatment, and found significant improvements in efficacy outcomes due to the strong effect size versus placebo
  • Reductions in the monthly number of migraine and headache days of at least moderate severity were significantly greater with fremanezumab versus placebo in male patients, and improvements were generally comparable to those observed in women
  • These results may be particularly meaningful for healthcare providers treating male patients, for whom the impact of migraine is often underestimated and undertreated
  • Podcast by Antoinette Maassen Van Den Brink, PhD

Key messages

  • This analysis evaluated the efficacy of fremanezumab in male migraine patients over 12 weeks of double-blind treatment, and found significant improvements in efficacy outcomes due to the strong effect size versus placebo
  • Reductions in the monthly number of migraine and headache days of at least moderate severity were significantly greater with fremanezumab versus placebo in male patients, and improvements were generally comparable to those observed in women
  • These results may be particularly meaningful for healthcare providers treating male patients, for whom the impact of migraine is often underestimated and undertreated

Podcast by Antoinette Maassen Van Den Brink, PhD

Antoinette Maassen Van Den Brink, PhD
Associate Professor
Department of Internal Medicine, Division of Vascular Medicine and Pharmacology, Erasmus MC
Rotterdam, Zuid-Holland, Netherlands

Dr. Antoinette Maassen van den Brink, PhD, is Associate Professor of Pharmacology at the Department of Internal Medicine, Erasmus MC, Rotterdam, The Netherlands. She obtained her PhD degree on the cardiovascular side effects of antimigraine drugs at the Department of Pharmacology, Erasmus University Rotterdam, in 1999. Since then, she has been studying the neurovascular aspects of migraine, with a special interest in the role of female sex hormones on its pathophysiology. Her research is translational in origin, including animal in vivo experimental models, human isolated tissue models, as well as human in vivo clinical models. She is a board member of the Dutch Headache Society, Dutch Pharmacology Society and founding board member of the Dutch Society for Gender and Health. Further, she serves as a board member for the European Headache Federation and the Federation of European Pharmacological Societies. She has received many prestigious research grants and awards from the American Headache Society, International Headache Society, Dutch Heart Foundation, Dutch Brain Foundation, the Netherlands Organisation for Health Research and Development, as well as the Netherlands Organisation for Scientific Research (NWO).

Antoinette Maassen Van Den Brink, MD: Amgen/Novartis (Other Activities) (Research Grant or Support, grant/research support)



Headache
Chronic Migraine


Scan to open on your mobile device